Xbrane Biopharma AB (publ) (STO:XBRANE)

Xbrane Biopharma AB Ratios and Metrics

Market cap in millions SEK. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 17, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	379	246	297	2,258	2,624	1,661
Market Cap Growth	-12.10%	-17.28%	-86.83%	-13.94%	58.03%	211.34%
Enterprise Value	504	386	371	2,133	2,285	1,544
Last Close Price	0.25	0.16	10.00	82.10	104.80	74.80
Forward PE	1.16	18.48	-	-	-	-
PS Ratio	1.36	1.24	1.25	39.19	245.05	-
PB Ratio	1.75	1.18	1.74	5.32	6.08	6.44
P/TBV Ratio	1.75	1.18	1.74	5.32	6.08	8.33
EV/Sales Ratio	1.81	1.94	1.56	37.03	213.37	-
Debt / Equity Ratio	0.69	0.92	1.35	0.09	0.10	0.02
Asset Turnover	0.35	0.27	0.36	0.08	0.02	-
Inventory Turnover	0.27	0.10	2.59	-	-	-
Quick Ratio	0.11	0.40	0.42	1.02	1.84	1.68
Current Ratio	1.22	1.13	1.41	2.17	2.55	1.98
Return on Equity (ROE)	-52.69%	-139.53%	-108.02%	-39.34%	-53.15%	-104.60%
Return on Assets (ROA)	-8.02%	-16.97%	-27.60%	-13.84%	-19.14%	-33.74%
Return on Capital (ROIC)	-12.92%	-31.60%	-42.83%	-20.32%	-29.80%	-62.58%
Earnings Yield	-42.42%	-108.25%	-130.56%	-7.64%	-7.18%	-13.61%
FCF Yield	-	-54.58%	-139.07%	-9.10%	-9.42%	-14.59%
Buyback Yield / Dilution	-1387.44%	-4184.96%	-12.26%	-8.38%	-30.25%	-61.86%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.